Consensus guidelines recommend use of granulocyte colony stimulating factor in patients
deemed at risk of chemotherapy‐induced neutropenia, however, these risk models are …

The goal of this mini-review is to summarize the collective experience of the authors for how
modeling and simulation approaches have been used to inform various decision points from …

In the oncology field, understanding the relationship between the dose administered and the
exerted effect is particularly important because of the narrow therapeutic index associated …

This study applied modeling and simulation (M&S) approaches to evaluate the sensitivity of
pegfilgrastim pharmacokinetics (PKs) and pharmacodynamics (PDs) to changes in dose …

Objective: Neutropenia is an adverse event commonly arising during intensive
chemotherapy of acute myeloid leukemia (AML). It is often associated with infectious …

Aims Recombinant PEGylated human granulocyte colony‐stimulating factor (pegfilgrastim)
is indicated for the reduction of chemotherapy‐induced neutropenia and prevention of …

High‐dose melphalan (HDM) is part of the conditioning regimen in patients with multiple
myeloma (MM) receiving autologous stem cell transplantation (ASCT). However, individual …

Acute exposure to high doses of radiation leads to severe myelosuppression, but few
treatments are currently available to treat hematopoietic syndrome of acute radiation …

Tripegfilgrastim is a long‐acting granulocyte colony‐stimulating factor (G‐CSF) that has
been used to prevent chemotherapy‐induced neutropenia in adults. This study aimed to …

Aims Granulocyte colony‐stimulating factor (G‐CSF) is frequently prescribed to prevent
chemotherapy‐induced neutropenia, but the administration schedule remains empirical in …